Sage Journals: Discover world-class research

Abstract

BACKGROUND:

Smac/DIABLO is a proapoptotic protein deregulated in breast cancer, with a controversial role as a tumor marker, possibly due to a lack of correlative mRNA and protein analyses.

OBJECTIVE:

To investigate the association of Smac/DIABLO gene and protein levels with clinical variables in breast cancer patients.

METHODS:

Smac/DIABLO mRNA expression was analyzed by qPCR in 57 frozen tissues, whereas protein levels were assessed by immunohistochemistry in 82 paraffin-embedded tissues. Survivin mRNA levels were also measured. In vitro assays were performed to investigate possible regulators of Smac/DIABLO.

RESULTS:

Higher levels of Smac/DIABLO mRNA and protein were found in estrogen receptor (ER)-positive samples ( $p=$ 0.0054 and $p=$ 0.0043, respectively) in comparison to ER-negative tumors. A negligible positive association was found between Smac/DIABLO and survivin expression. In vitro assays showed that Smac/DIABLO is not regulated by ER and, conversely, it does not participate in ER expression modulation.

CONCLUSIONS:

mRNA and protein levels of Smac/DIABLO were increased in ER-positive breast tumors in comparison with ER-negative samples, although the mechanism of this regulation is still unknown. Public databases showed a possible clinical relevance for this association.

Keywords

Smac/DIABLO survivin breast cancer estrogen receptor

1. Introduction

Breast cancer is the leading cause of death by cancer in the female population worldwide [1]. In Mexico, most patients have locally advanced or metastatic disease when first seen at the oncology clinic [2]. Several factors such as limited access to prevention and early detection of breast cancer have been proposed as the cause of this late diagnosis [3]. In addition, Mexican women with breast cancer have a mean age at diagnosis of 52 years [2], which is at least a decade younger than women in the U.S. [4]. In Mexico, as in other countries, most patients have ER-positive breast tumors (60%), whereas 23% are human epidermal growth factor receptor 2 (HER2)-positive tumors [2]. Breast cancer heterogeneity makes hard to give all patients an optimal treatment and predict the individual risk of metastasis. Currently at the time of diagnosis, the potential for tumor recurrence and general prognosis are estimated according to clinicopathological features such as tumor size, grade, involvement of lymphatic vessels, expression of ER, progesterone receptor (PR), and HER2 [5, 6]. However, these criteria have been insufficient to help in the early detection and prognosis of this disease [7].

Apoptosis resistance is an important mechanism for tumor development and progression [8]. Smac (second mitochondria-derived activator of caspases) [9], also known as DIABLO (Direct IAP binding protein with low pI) [10] is a pro-apoptotic protein released into the cytosol in response to noxious stimuli, where it binds and inhibits members of the Inhibitors of Apoptosis Proteins (IAP) family, promoting caspase activation and cell death [9]. The mitochondrial release of Smac/DIABLO during apoptosis can be regulated by survivin, a IAP family member [11]. Altered Smac/DIABLO expression has been observed in several tumors. Low levels of Smac/DIABLO are prognostic for poor prognosis in bladder cancer [12], renal cell carcinoma [13] and lung cancer [14]. However, in cervical cancer [15], gastric adenocarcinomas [16] and leukemia [17] Smac/DIABLO levels are increased as compared to healthy tissue; and in the latter case, high levels of Smac/DIABLO are associated with poor prognosis.

Conflicting results have been found when the expression of Smac/DIABLO was analyzed in breast tumors. Pluta and collaborators found a diminished expression by flow cytometry of Smac/DIABLO in tumor samples in comparison with benign breast tumors. In addition, Smac/DIABLO expression inversely correlated with tumor stage [18]. Moreover, in 102 samples of invasive ductal carcinoma, Zhang and colleagues observed cytoplasmic staining of the protein which was more prevalent in the HER2-positive group. No other association between Smac/DIABLO expression and clinical features was found [19]. Independently, Mansour and coworkers analyzed Smac/DIABLO and survivin mRNA expression by qualitative RT-PCR in 37 benign breast tumors and 48 malignant tumors. This group found a reduced Smac/DIABLO expression in the breast cancer group and an inverse relation with survivin expression. Smac/DIABLO downregulation showed a positive correlation with ER, but no additional correlation with other clinicopathological feature or risk factor [20].

In the present work, we analyzed the Smac/DIABLO gene and protein expression in two different sample groups of Mexican breast cancer patients. We searched for a correlation between Smac/DIABLO expression, survivin expression and clinicopathological features. We found a negligible correlation between Smac/DIABLO and survivin expression levels. Interestingly, we observed a positive correlation between Smac/DIABLO and ER expression at both mRNA and protein levels. Our finding was supported by data from public databases, where a positive correlation between the proteins Smac/DIABLO and ER was found in breast tumors samples. Additionally, we analyzed public microarray gene expression data and found that Smac/DIABLO expression has a prognostic value for breast tumor patients, particularly for patients with ER-positive tumors. Additionally, we performed in vitro assays and found that Smac/DIABLO is neither a target gene of ER nor participates in ER expression regulation.

2. Materials and methods

2.1 Patients

The first group of samples was collected during the 2008–2011 period at the Fundación contra el Cáncer de Mama (FUCAM) after informed consent. Tumor samples were collected during surgery, a total of 57 samples were analyzed. The protocol was reviewed and approved by the Ethics and Research committees of the National Institute of Genomic Medicine (INMEGEN) and FUCAM in Mexico City (CE2009/11). After macroscopic inspection by the pathologist, sections of tumor were frozen in liquid nitrogen and stored at $-$ 80 ${}^{\circ}$ C until further processing. A section of the tissue was formalin-fixed to confirm the diagnosis and assess tumor cell content and grade by hematoxylin and eosin (H&E) staining. Estrogen and progesterone receptors, as well as HER2 expression, were evaluated using the ER/PR pharmDx and the HercepTest kits, respectively, following the manufacturer’s instructions. Histopathological analysis and evaluation of immunohistochemical results were performed according to standard clinical protocols by two trained pathologists at the National Institute of Genomic Medicine and the FUCAM in Mexico City. After tumor cell content evaluation, RNA was extracted from the frozen tissue with the AllPrep DNA/RNA mini kit (Qiagen, Valencia, CA, USA) according to the manufacturer’s instructions. RNA integrity was analyzed by capillary electrophoresis using the Bioanalyzer system (Agilent, Santa Clara, CA, USA). 1 $\mu$ g of RNA was retrotranscribed to cDNA using SuperScript III first-strand kit (Invitrogen, Carlsbad, CA, USA) for further evaluation of Smac/DIABLO and GAPDH expression by qPCR.

2.2 Tissue microarray construction

For Smac/DIABLO protein analysis, paraffin- embedded tissues were obtained from the Oncology Hospital in the XXI Century National Medical Center; since these tissues constituted residual material, their use does not represent a risk for patient diagnosis. Tumor tissues from 82 patients were embedded in paraffin, and 4 mm sections were stained with hematoxylin and eosin to select morphologically representative areas. Tissues selected from each specimen were punched with a 1 mm needle and transferred to a recipient paraffin block using a Tissue Microarray ATA 100 Chemicon (Temecula, CA, USA). Then, 4 mm sections of these tissue arrays were sectioned and placed onto positive charged slides (VWR Superfrost Plus).

2.3 Immunohistochemistry of breast cancer tissues

For Smac/DIABLO protein analysis panel, whole tissue sections were stained with Estrogen Receptor (Ventana CONFIRM anti-ER, Roche, Strasbourg, France), Progesterone Receptor (Ventana CONFIRM anti-PR), HER-2/neu antibody (Ventana, PATHWAY anti-HER-2/neu) and Smac/DIABLO mouse mAb (Cell Signaling, Danvers, MA, USA). Immunohistochemistry was performed with the Ventana Ultraview DAB Detection Kit (Ventana). Diaminobenzidine was used as the chromogen and hematoxylin as the nuclear counterstain. All slides were processed in a Ventana BenchMark XT processor (Ventana, Tuczon, AZ, USA) and mounted with synthetic resin. Slides were scanned in ScanScope CS2 (Aperio) and image analysis was performed in Image J. Two independent observers reviewed the slides and estimated the percentage of tumor cells and staining intensities scores. Smac/DIABLO score expression is the product of the percentage of positive cells multiplied by the immunostaining intensity.

2.4 The Cancer Genome Atlas (TCGA) samples

We used Regulome Explorer (http://www.cancerregu lome.org/software.html) web-based tool to analyze data from the public sample database TCGA to obtain information about Smac/DIABLO and ER expression in breast tumors. Comparisons between the expressions of both genes were performed with the tool All Pairs Analysis, using the database of breast tumors from February 2013. Additionally, the expression of Smac/DIABLO between the Luminal B (ER-positive) and Basal (ER-negative) subtypes of breast cancer was compared with this tool.

2.5 Cell lines

All cell lines were obtained from American Type Culture Collection (Manassas, VA, USA) with the exception of the SKBR-3 cell line, which was kindly donated by PhD Fernando Enriquez Rincon. SKBR-3 cell line was authenticated by short tandem repeat (STR)-profiling using AmpFLSTR ${}^{\text{TM}}$ Identifiler ${}^{\text{TM}}$ PCR Amplification Kit (Applied Biosystems). MCF-7, MDA-MB-468, MDA-MB-453 and MDA-MB-361 were grown in Dulbecco’s Modified Eagle Medium (DMEM) supplemented with Fetal Bovine Serum (FBS) at 5%. SKBR-3 cells were cultured in McCoy’s 5A medium supplemented with 5% of FBS. T47D and ZR-75-1 cells were grown in RPMI1640 medium with 5% of FBS. BT-20 cell line was grown in Eagles’s Minimum Essential Medium (EMEM) supplemented with 10% of SFB. The cells were cultured at 37 ${}^{\circ}$ C with 5% of CO ${}_{2}$ in a humidified atmosphere.

2.6 Protein extraction

Total protein was obtained from panel of breast cancer cell lines with RIPA buffer. Briefly, cells were grown up to 80% of confluency and then were washed with PBS 1X, cells were scrapped in PBS 1X and centrifuged to obtain cell pellet. Cellular pellet was resuspended in RIPA buffer, homogenized and incubated in ice for 10 min. After incubation samples were centrifuged at 10,000 rpm for 30 min. The supernatant was recovered as total protein extract. Proteins from long-term estrogen-deprived (LTED) MCF-7 cells and Smac/DIABLO-overexpressing cells were obtained with M-PER Mammalian Protein Extraction Reagent (Thermo Scientific, Waltham, MA, USA) following manufacturer’s instructions, with minor modifications. Briefly, cells were washed with PBS 1X and then were scrapped with PBS 1X and centrifuged at 1,000 rpm for 5 min. The cell pellet was resuspended in 100–200 $\mu$ l of M-PER Reagent, incubated at room temperature with agitation by 10 min and centrifuged at 13,000 rpm for 15 min. The supernatant was saved as the protein extract and stored at $-$ 70 ${}^{\circ}$ C until use.

2.7 Western blot

Whole-cell lysates were separated by SDS gel and transferred to 0.22 $\mu$ m PVDF membranes (Bio-Rad, Hercules, CA, USA) for 20 min at 12 V in a semidry transfer chamber (Bio-Rad, Hercules, CA, USA). Membranes were blocked for 1 h with 5% nonfat dry milk in Tris-buffered saline with Tween (TBST) (150 mM NaCl, 15 mM Tris-HCl (pH 7.5), and 0.1% Tween 20) and then incubated with the primary antibody in blocking solution at 4 ${}^{\circ}$ C overnight. After incubation with corresponding secondary antibodies for 1 h at room temperature and subsequent washes, signals were detected by using the ChemiDoc MP System (Bio-Rad, Hercules, CA, USA). The intensity of the signals was analyzed with the Image Lab Software (Bio-Rad, Hercules, CA, USA).

2.8 Chemicals

17 $\beta$ -estradiol (E2) and Fulvestrant (ICI 182,780) were purchased from Sigma (St Louis, MO, USA). Anti Smac/DIABLO antibody (1:1000 dilution), Anti ERalpha antibody (1:1000 dilution) and anti-rabbit antibody (1:2000 dilution) were purchased from Cell Signaling (Danvers, MA, USA). Anti GAPDH antibody (1:200 dilution) was purchased from Santa Cruz Biotechnologies (Dallas, TX, USA). Anti $\beta$ -tubulin antibody (1:5000 dilution) was purchased from Amersham (UK). Anti-mouse antibody (1:2000 dilution) was purchased from Promega (Madison, WI, USA).

2.9 Plasmids

For Smac/DIABLO promoter assays, 1.5 kb from the genomic 5’ untranslated region (UTR) of Smac/ DIABLO were amplified and cloned in the pSEAP2 vector (Clontech, Mountain View, CA, USA) as previously reported [21]. The construct, named pSEAP2-1.5kbsmacpromoter, was verified by capillary sequencing. An absent region of 34 bp was founded in our sequence, and this deletion was also found in the genomic 5’ UTR of Smac/DIABLO from HEK293 cells when the sequences were compared with the Homo sapiens 12 BAC RP11-512M8 sequence (GenBank: AC048338.29). The vector pSEAP2-Basic (Clontech, Mountain View, CA, USA) was used as control. The ORF of Smac/DIABLO was amplified by PCR with the following primers, forward 5’-GCGCGGATCCATGGCGGCTCTGAAGAGTTGGCT-3’; reverse 5’-AGCTCT CTAGACTCAGGCCCTCAATCCTCACGC-3’. The amplified product was cloned into pCR2.1-TOPO vector (Invitrogen, Carlsbad, CA, USA). The construction with the transgene was amplified and the ORF of Smac/DIABLO was obtained with restriction enzymes, the fragment was cloned into the multiple cloning site of pQCXIP (Clontech, Mountain View, CA, USA), in the region flanked by NotI and BamHI sites. The correct insertion of the ORF was verified by enzymatic digestion. pQCXIP empty vector was used as control.

2.10 RT and qPCR

1 $\mu$ g of total RNA obtained from E2-treated cells, estrogen-deprived cells and Smac-overexpressing cells, was used to synthesize cDNA using High-capacity cDNA reverse transcription kit (Applied Biosystems, Carlsbad, CA, USA) following manufacturer’s instructions. qPCRs were carried out on a ViiA7 (Applied Biosystems, Carlsbad, CA, USA) detection system using Taqman ${}^{\@setsize{\scriptsize}{8pt}{\viipt}{\@viipt}\textregistered}$ Universal PCR Master mix (Applied Biosystems, Carlsbad, CA, USA) and SYBR Select Master Mix (Applied Biosystems, Carlsbad, CA, USA) according to manufacturer’s instructions. Taqman Gene Expression Assay primer-probe sets (Applied Biosystems, Carlsbad, CA, USA) used were, Hs01059480_g1 for SMAC, HS00266705_G1 for GAPDH and Hs0097612_mH for survivin. The cycling parameters were as follow: 95 ${}^{\circ}$ C for 10 m for 1 cycle, 95 ${}^{\circ}$ C for 15 s, 60 ${}^{\circ}$ C for 1 m for 40 cycles. For ER expression, the primers were, forward primer 5’-CCACCAACCAGTGCACCATT-3’, reverse primer 5’-GTTC TTTTCGTATCCCACCTTTC-3’; conditions: 95 ${}^{\circ}$ C for 2 m for 1 cycle; 95 ${}^{\circ}$ C for 30 s, 61 ${}^{\circ}$ C for 30 s, 72 ${}^{\circ}$ C for 30seg. For pS2 expression, the primers were, forward primer 5’-TGACTCGGGGTCGCCTTTGGAG-3’, reverse primer 5’-GTGAGCCGAGGCACAGCTGCAG-3’; conditions: 95 ${}^{\circ}$ C for 2 m for 1 cycle; 95 ${}^{\circ}$ C for 30 s, 63 ${}^{\circ}$ C for 30 s, 72 ${}^{\circ}$ C for 30 s. Normalized data from breast cancer patients were analyzed with a relative standard curve method, and data from cultured cells were analyzed with the 2 ${}^{-\Delta\Delta\text{Ct}}$ method.

2.11 E2 treatment

MCF-7 and T47D cells cultured in normal conditions were seeded in twelve-well plates, the next day, cells were washed twice with PBS 1X and once with DMEM phenol red-free (Life Technologies, Carlsbad, CA, USA) supplemented with 5% charcoal-stripped bovine serum (Life Technologies, Carlsbad, CA, USA). After 5 days of culture in phenol red-free medium, cells were treated with 10 nM E2 and ethanol, as vehicle, for 24 h. RNA was extracted at this time.

2.12 Gene reporter assays

MCF-7 cells were transiently transfected with pSEAP2-Basic vector (Clontech, Mountain View, CA, USA) and pSEAP2-1.5kbsmacpromoter plasmid in a ratio of 1:200 with pMetLuc2-Control vector (Clontech, Mountain View, CA, USA) as an internal control. 24 h postransfection cells were seeded in a 24-well plate and the next day washed twice with PBS1X and once with DMEM w/o phenol red (Life Technologies, Carlsbad, CA, USA) supplemented with 5% of charcoal-stripped fetal bovine serum (Life Technologies, Carlsbad, CA, USA). Cells were maintained in this medium for 3 days before hormone treatment. Cells were stimulated with E2 10 nM for 24 h. Medium was collected for further analysis. Non-transfected cells were stimulated under the same conditions for pS2 mRNA expression analysis by qPCR. SEAP activity was analyzed with GreatEscape SEAP Chemiluminescence Kit 2.0 (Clontech, Mountain View, CA, USA) and luciferase activity with Ready-To-Glow Secreted Luciferase Reporter Assay (Clontech, Mountain View, CA, USA) according to manufacturer’s instructions.

2.13 Long-term estrogen-deprived (LTED) MCF-7 cells establishment and experiments

To establish LTED MCF-7 cells, the cells were cultured in DMEM phenol red-free (Life Technologies, Carlsbad, CA, USA) supplemented with 5% charcoal-stripped bovine serum (Life Technologies, Carlsbad, CA, USA) for five to seven months. At this time, cells were exposed to E2 10 nM for 24 h or with Fulvestrant (1 $\mu$ M) for 48 h and RNA or protein were obtained for further analysis.

2.14 Cell transfection

For transient transfection of MCF-7 cells, 5.8 $\times$ 10 ${}^{5}$ cells were seeded in a well of a six-well plate. Next day, cells were transfected with X-Fect (Takara Bio, Mountain View, CA, USA) and 5 $\mu$ g of plasmid, following the manufacturer’s instructions. Cells were incubated overnight with a mixture of lipid-DNA. 48 h postransfection, cells were processed for RNA and protein extraction.

2.15 Statistical analysis

Statistical analysis was performed with the GraphPad Prism 5.0 (GraphPad Software Inc.) software. Intergroup differences were analyzed by using Mann-Whitney $U$ -test or Kruskal-Wallis ANOVA test. Correlations between variables were assessed by the Spearman rank correlation coefficient. Differences between conditions were analyzed with Student- $t$ test. Results were considered statistically significant if the $p$ -value was $<$ 0.05.

3. Results

3.1 Smac/DIABLO expression is higher in ER-positive breast tumors and is associated with a worse prognosis in breast cancer patients

First, we evaluated Smac/DIABLO mRNA expression by qPCR in a panel of 57 breast cancer samples. Table 1 shows the clinicopathological characteristics of the samples. Infiltrating ductal carcinoma was the most frequent diagnosis (82%), and the mean age of the patients was 55 years. Approximately 68% of the samples were ER-positive, 56% were PR positive and 18% were HER2 positive. All samples expressed Smac/DIABLO mRNA, although at different levels. We found higher levels of Smac/DIABLO in the 50 years old or older group ( $p=$ 0.027) (Table 2) in comparison with the younger patients. Moreover, we found lower levels of Smac/DIABLO expression in grade III tumors as compared with grade II ones ( $p=$ 0.045) (Table 2). Smac/DIABLO expression was higher in ER-positive tumors ( $p=$ 0.005) (Table 2, Fig. 1A) in comparison with ER-negative samples and was not associated with PR or HER2 status.

Table 1
Clinicopathological features of mRNA analysis breast cancer group ( $N=$ 57)

Feature	Number of patients (%)
Age (years)
Median (range)	55 (37–89)
$<$ 50 years	18 (31.57%)
$\geqslant$ 50 years	39 (68.42%)
Tumor size	$N=$ 56 ${}^{\text{a}}$
T1 ( $<$ 2 cm)	21 (37.5%)
T2 and T3 ( $\geqslant$ 2 cm)	35 (62.5%)
Grade	$N=$ 48 ${}^{\text{a}}$
I	3 (6.25%)
II	35 (72.91%)
III	10 (20.83%)
Stage
I	10 (17.54%)
IIA	22 (38.59%)
IIB	15 (26.31%)
IIIA	5 (8.77%)
IIIB	4 (7.01%)
IIIC	1 (1.75%)
Pathology
Infiltrating ductal	47 (82.45%)
Mixed	2 (3.50%)
Ductal in situ	1 (1.75%)
Infiltrating lobulillar	4 (7.01%)
Medullary	1 (1.75%)
Infiltrating papilar	1 (1.75%)
Infiltrating mucinous	1 (1.75%)
Menopausal status	$N=$ 28 ${}^{\text{a}}$
Premenopausal	15 (53.57%)
Postmenopausal	13 (46.42%)
Menarche	$N=$ 56 ${}^{\text{a}}$
Median (range)	13 (10–16)
Pregnancies	$N=$ 56 ${}^{\text{a}}$
Pregnancy (median, range)	53 (94.64%) (3, 1–13)
No pregnancy	3 (5.35%)
Age of first child	$N=$ 52 ${}^{\text{a}}$
Median (range)	22 (14–42)
Breast-feeding	$N=$ 53 ${}^{\text{a}}$
Yes	47 (88.67%)
No	6 (11.32%)
ER status
Positive	39 (68.42%)
Negative	18 (31.57%)
PR status
Positive	32 (56.14%)
Negative	25 (43.85%)
HER2 status	$N=$ 55 ${}^{\text{a}}$
Positive	10 (18.18%)
Negative	45(81.81%)

${}^{\text{a}}$ , Number of patients with available information that were included in the analysis. ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2.

Table 2

Correlation between Smac/DIABLO mRNA expression and breast cancer patients clinicopathological features ( $N=$ 56)

Feature	Smac/DIABLO expression Median (range)	$p$ -value
Age
$<$ 50 years	25.7 (10.42–84.72)	0.02703 ${}^{*}$
$\geqslant$ 50 years	30.9 (5.19–58.98)
Tumor size
T1 ( $<$ 2 cm)	28.6 (5.19–53.59)	0.4597
T2 and T3 ( $\geqslant$ 2 cm)	27.2 (7.38–84.72)
Grade	$N=$ 47 ${}^{\text{a}}$
I	37.4 (31.49–53.59)	0.0446 ${}^{*}$
II	28.7 (15.14–84.72)
III	20.4 (5.19–44.63)
Stage
I	27.9 (16.13–49.17)	0.5874
IIA	27.1 (5.19–53.59)
IIB	27.7 (10.42–84.72)
IIIA	28.7 (7.38–35.21)
IIIB	43.6 (21.04–58.98)
IIIC	19.5
Menopausal status	$N=$ 39 ${}^{\text{a}}$
Premenopausal	26.4 (10.42–84.72)	0.5975
Postmenopausal	29.6 (5.19–58.98)
Menarche	$N=$ 55 ${}^{\text{a}}$
$<$ 13 years	26.9 (10.42–84.72)	0.9389
$\geqslant$ 13 years	28.7 (5.19–57.30)
Pregnancies	$N=$ 52 ${}^{\text{a}}$	0.1728
	3 (1–13)
Age of first child	$N=$ 51 ${}^{\text{a}}$	0.4650
	22 (14–42)
Breast-feeding	$N=$ 52 ${}^{\text{a}}$
Yes	28.7 (5.19–84.72)	0.2465
No	25.7 (7.38–35.21)
ER status
Positive	30.5 (16.13–84.7)	0.0054 ${}^{**}$
Negative	25.9 (5.19–40.18)
PR status
Positive	28.8 (15.14–57.30)	0.3675
Negative	26.9 (5.19–84.72)
HER2 status	$N=$ 54 ${}^{\text{a}}$
Positive	27.39 (15.14–57.30)	0.8521
Negative	27.71 (5.19–84.72)

${}^{\text{a}}$ , Number of patients with available information that were included in the analysis; ${}^{*}$ , $p<$ 0.05; ${}^{**}$ , $p<$ 0.01. ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2.

Table 3

Correlation between survivin mRNA expression and breast cancer patients clinicopathological features ( $N=$ 57).

Feature	Survivin expression Median (range)	$p$ -value
Age
$<$ 50 years	26.93 (2.36–116.38)	0.3087
$\geqslant$ 50 years	20.57 (5.31–113.63)
Tumor size
T1 ( $<$ 2 cm)	18.88 (2.36–45.68)	0.0134 ${}^{*}$
T2 and T3 ( $\geqslant$ 2 cm)	26.93 (5.31–116.38)
Grade	$N=$ 48 ${}^{\text{a}}$
I	17.49 (5.83–23.67)	0.325
II	22.91 (2.36–116.38)
III	30.10 (7.66–71.06)
Stage
I	16.55 (2.36–56.99)	0.1102
IIA	20.57 (5.31–113.63)
IIB	27.36 (13.09–116.38)
IIIA	45.67 (13.14–79.16)
IIIB	16.99 (5.93–26.62)
IIIC	28.12
Menopausal status
Premenopausal	25.91 (7.01–116.38)	0.7527
Postmenopausal	21.64 (2.36–113.63)
Menarche	$N=$ 56 ${}^{\text{a}}$
$<$ 13 years	22.72 (2.36–116.38)	0.4000
$\geqslant$ 13 years	23.36 (5.83–113.63)
Pregnancies	$N=$ 53 ${}^{\text{a}}$	0.9976
	3 (1–13)
Age of first child	$N=$ 52 ${}^{\text{a}}$	0.5304
	22 (14–42)
Breast-feeding	$N=$ 53 ${}^{\text{a}}$
Yes	23.36 (2.36–116.38)	0.8480
No	22.65 (13.14–79.16)
ER status
Positive	23.66 (2.36–116.38)	0.3528
Negative	21.54 (5.31–79.16)
PR status
Positive	22.78 (2.36–116.38)	0.4105
Negative	25.45 (5.31–113.63)
HER2 status	$N=$ 55 ${}^{\text{a}}$
Positive	20.44 (12.01–56.99)	0.7068
Negative	24.74 (2.36–116.38)

${}^{\text{a}}$ , Number of patients with available information that were included in the analysis; ${}^{*}$ , $p<$ 0.05. ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2.

Table 4

Correlation between Smac/survivin mRNA expression and breast cancer patients clinicopathological features ( $N=$ 56)

Feature	Smac/survivin Median (range)	$p$ -value
Age
$<$ 50 years	0.79 (0.40–6.83)	0.1902
$\geqslant$ 50 years	1.71 (0.27–5.39)
Tumor size
T1 ( $<$ 2 cm)	1.95 (0.61–6.83)	0.0045 ${}^{**}$
T2 and T3 ( $\geqslant$ 2 cm)	0.82 (0.40–5.06)
Grade	$N=$ 47 ${}^{\text{a}}$
I	2.26 (2.13–5.39)	0.0017 ${}^{**}$
II	1.16 (0.27–6.83)
III	0.67 (0.30–1.73)
Stage
I	1.96 (0.61–6.83)	0.0130 ${}^{*}$
IIA	1.75 (0.27–5.39)
IIB	0.85 (0.40–2.29)
IIIA	0.56 (0.44–1.73)
IIIB	3.15 (1.05–5.02)
IIIC	0.69
Menopausal status	$N=$ 39 ${}^{\text{a}}$
Premenopausal	0.96 (0.40–4.12)	0.7002
Postmenopausal	1.49 (0.27–6.83)
Menarche	$N=$ 55 ${}^{\text{a}}$
$<$ 13 years	1.74 (0.40–6.83)	0.2629
$\geqslant$ 13 years	0.96 (0.27–5.39)
Pregnancies	$N=$ 52 ${}^{\text{a}}$	0.8659
	3 (1–13)
Age of first child	$N=$ 51 ${}^{\text{a}}$	0.2400
	22 (14–42)
Breast-feeding	$N=$ 52 ${}^{\text{a}}$
Yes	1.20 (0.27–6.83)	0.1988
No	0.88 (0.44–1.26)
ER status
Positive	1.23 (0.27–6.83)	0.2318
Negative	0.96 (0.30–5.06)
PR status
Positive	1.71 (0.44–6.83)	0.1103
Negative	0.96 (0.27–5.06)
HER2 status	$N=$ 54 ${}^{\text{a}}$
Positive	1.17 (0.51–4.10)	0.7174
Negative	1.11 (0.27–6.83)

Table 5

Relationship between Smac/DIABLO score expression ( $N=$ 82) and breast cancer patients clinicopathological features

Feature	Number of patients	Smac/DIABLO score expression correlation $p$ -value
Age (years)	$N=$ 69 ${}^{\text{a}}$
Median (range)	59 (25–84)	0.1578
$<$ 50 years	48 (69.56%)
$\geqslant$ 50 years	21 (30.43%)
Grade	$N=$ 57 ${}^{\text{a}}$
I	7 (12.28%)	0.8333
II	28 (49.12%)
III	22 (38.59%)
Menarche	$N=$ 67 ${}^{\text{a}}$
Median (range)	13 (9–16)	0.5631
$<$ 13 years	31 (46.26%)
$\geqslant$ 13 years	36 (53.73%)
Pregnancies (median, range)	$N=$ 68 ${}^{\text{a}}$	0.5319
	(3, 0–11)
ER status	$N=$ 78 ${}^{\text{a}}$
Positive	51 (65.38%)	0.0043 ${}^{**}$
Negative	27 (34.61)
PR status	$N=$ 61 ${}^{\text{a}}$
Positive	32 (62.45%)	0.1451
Negative	29 (47.54%)
HER2 status	$N=$ 79 ${}^{\text{a}}$
Positive	17 (21.51%)	0.6766
Negative	62 (78.48%)

${}^{\text{a}}$ , Number of patients with available information that were included in the analysis; ${}^{**}$ , $p<$ 0.01. ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2.

Smac/DIABLO sensitizes cells to apoptosis by binding and inhibiting IAP function [9]. Survivin is an important member of IAP family and it is overexpressed in several tumor types. Due to the role of these two proteins in cell death regulation, their expression have been associated with poor prognosis in several malignancies [22, 23, 24, 25]. Therefore, we analyzed survivin mRNA expression in our samples. Smac/DIABLO and survivin expression showed a negligible positive correlation (Spearman correlation $=$ 0.23, $p>$ 0.05). Survivin expression was only significantly higher in T2/T3 tumors ( $p=$ 0.013) when compared to T1 samples (Table 3). Interestingly, when the expression of both genes was considered as a ratio, a low Smac/survivin ratio (high levels of survivin and low levels of Smac/DIABLO) was associated to higher size and more advanced grade and stage ( $p=$ 0.0045, $p=$ 0.0017 and $p=$ 0.013, respectively; Table 4).

We also evaluated the expression of the Smac/ DIABLO protein by immunohistochemistry in a tissue microarray of 82 independent breast tumor samples. Table 5 shows the clinicopathological characteristics of these patients and the correlation with the Smac/DIABLO staining score. The score was calculated multiplying the staining intensity, which was evaluated as negative (0), weak (1), moderate (2), or strong (3) (Fig. 1C) and by the percentage of positive cells, which ranged from 80 to 100%. Smac/DIABLO protein was mostly cytosolic. Interestingly, Smac/DIABLO staining score was higher in ER-positive tumors ( $p=$ 0.0043) when compared to ER-negative tumors (Table 5, Fig. 1B). No additional significant correlations were found.

To independently validate our findings, we searched in data from the Cancer Genomic Atlas initiative (TCGA). We found that Smac/DIABLO protein and ER mRNA showed a negligible but significative positive correlation ( $R=$ 0.298, $p<$ 0.0001) (Fig. 2A). Interestingly, Smac/DIABLO and ER proteins also showed a significative positive correlation ( $R=$ 0.416, $p<$ 0.0001) (Fig. 2B). In addition, Smac/DIABLO protein and the phosphorylated (S118) and active ER protein also showed a significative low positive correlation ( $R=$ 0.303, $p<$ 0.0001) (Fig. 2C). Accordingly, in this database, higher levels of Smac/DIABLO protein in the Luminal B subtype of breast cancer in comparison with the Basal subtype were found ( $p<$ 0.0001) (Fig. 2D). All together, these results suggested a relation between Smac/DIABLO and ER in breast cancer. To our knowledge, this is the first report where this association has been identified. This finding prompted us to search for the clinical relevance of this association.

Figure 1.

Smac/DIABLO mRNA and protein levels are higher in ER positive breast cancer samples. (A) Smac/DIABLO mRNA levels were analyzed by qPCR in breast tumors samples grouped according with ER status. The graph shows the median with interquartile range (black line). (B) Smac/DIABLO protein expression was analyzed by immunohistochemistry in breast cancer samples considering the ER status. The median value of IHC score and interquartile range (black line) are shown in the graph. (C) Images of Smac/DIABLO immunostaining levels (200X). The scale of immunostaining intensity is shown inside the images. ${}^{**}$ , $p<$ 0.01. Statistical significances were determined by Mann-Whitney U test.

Figure 2.

Smac/DIABLO protein correlations with ER in TCGA breast cancer samples. Expression data from the Cancer Genomic Atlas consortium (TCGA) were analyzed with Regulome Explorer tool (http://explorer.cancerregulome.org/all_pairs/) to assess associations between Smac/DIABLO and ER (A) Smac protein vs ER gene (395 samples, Spearman $r=$ 0.298, $p<$ 0.0001). (B) Smac protein vs ER protein (303 samples, Spearman $r=$ 0.416, $p<$ 0.0001). (C) Smac protein vs ER pS118 (410 samples, Spearman $r=$ 0.303, $p<$ 0.0001). (D) Smac protein expression in Luminal B and Basal breast cancer subtypes. The graph shows mean and the 95% CI (167 samples, $p<$ 0.0001, Mann-Whitney test). RPPA, Reverse Phase Protein Array.

Figure 3.

Higher expression of Smac/DIABLO in patients with ER-positive breast cancer is associated to a worse prognosis. Kaplan Meier plots of overall survival (A, C, E) and distant metastases free survival (B, D, F) of all breast cancer patients (A and B), patients with ER positive tumors (C and D), and patients with ER negative tumors (E and F). Samples were splitted according to Smac/DIABLO gene expression in high (red line) and low (black line) expression groups. The data presented in this figure were obtained from the public database KM-plotter (www.kmplot.com). The expression of Smac/DIABLO mRNA (Affymetrix ID 219350_s_at) and its relationship with survival of breast cancer patients was analyzed with this tool.

Figure 4.

Smac/DIABLO protein levels are higher in ER-positive breast cancer cell lines. (A) Quantitative data of Smac/DIABLO levels were analyzed by immunoblot in breast cancer cell lines with different status of ER. The reported status of ER is indicated in the graph. The experiment was done by duplicate and the data were normalized with GAPDH expression. The graph shows the mean value ( $n=$ 2). (B) Breast cancer cell lines from incise (A) were grouped by ER status and the expression of Smac/DIABLO was compared between groups. The results are shown as mean value. (C) Representatives blots of ER, Smac/DIABLO and GAPDH.

Figure 5.

Smac/DIABLO expression is not modulated by estradiol in ER-positive breast cancer cell lines. T47D (A) and MCF-7 cells (B) were exposed to E2 (10 nM) for 24 h and Smac/DIABLO and pS2 expression were analyzed by qPCR after incubation. Graphs show fold change mean $\pm$ SEM ( $n=$ 3). (C) Upper image, Smac/DIABLO 5’ untranslated sequence (UTR) (1.5 kb) with predicted ER binding sites (bold letters) and the absent region (gray letters). Lower image, scheme of ER binding sites (black portion) and the absent region (gray portion) in Smac/DIABLO 5’ UTR region, the position in the sequence is indicated with the numbers. Arrows indicate the putative transcription initiation site. (D) Luciferase quantitation of gene reporter assay of MCF-7 cells transfected with Smac 5’ UTR construct and stimulated with E2 (10 nM) for 24 h. The graph shows the mean $\pm$ SEM of three biological replicates. (E) Untransfected cells were stimulated as in (D), and pS2 expression was analyzed by qPCR. Graph shows fold change mean $\pm$ SEM ( $n=$ 3). ns, not significant, ${}^{*}$ , $p<$ 0.05, ${}^{**}$ , $p<$ 0.00). Data were analyzed with Student- $t$ test.

Figure 6.

ER does not regulate the expression of Smac/DIABLO in LTED MCF-7 cells. (A) ER levels in MCF-7 cells cultured in absence of estrogen by 5 months were analyzed by immunoblot. $\beta$ -tubulin expression was used as control loading. (B) Smac/DIABLO and pS2 mRNA levels were measured by qPCR, in LTED MCF-7 cells exposed to E2 (10 nM) for 24 h. Data were normalized with GAPDH expression. (C) Representative image of ER and Smac/DIABLO immunoblots of LTED MCF-7 cells treated with Fulvestrant for 48 h. The expression of $\beta$ -tubulin was used as a control. (D) Densitometric analysis of Smac/DIABLO and ER protein levels in LTED MCF-7 cells treated with Fulvestrant. The graph shows the Smac/DIABLO and ER mean intensity in three biological replicates (mean $\pm$ SEM). Data were analyzed with Student- $t$ test. ns, not significant; ${}^{**}$ , $p<$ 0.01; ${}^{***}$ , $p<$ 0.001.

Figure 7.

Smac/DIABLO does not regulate ER expression in MCF-7 cells. MCF-7 cells were transiently transfected with the open reading frame of Smac/DIABLO and Smac/DIABLO overexpression and its effect on modulation of ER expression were evaluated after 48 h. (A) Image of representatives immunoblots. (B) Densitometric analysis of immunoblots of Smac/DIABLO and ER. The expression of $\beta$ -tubulin was evaluated as a control. (C) Smac/DIABLO and ER mRNAs quantification by qPCR. The graphs show the mean $\pm$ SEM ( $n=$ 3). Results were analyzed with Student- $t$ test. ns, not significant; ${}^{*}$ , $p<$ 0.05. C, control; OE, overexpression.

Unfortunately, information regarding to patient’s survival was unavailable; therefore, to assess the effect of Smac/DIABLO expression on breast cancer patients’ survival, we searched an online database (www. kmplot.com) [26]. Data of Smac/DIABLO mRNA expression, assessed by microarrays, were analyzed. First, we investigated whether the levels of Smac/DIABLO were associated with survival of breast cancer patients, irrespective of their ER status. We found that breast cancer patients with high levels of Smac/DIABLO expression had a lower overall survival (OS) (1402 samples, $p=$ 0.0073, HR (hazard ratio) $=$ 1.37) (Fig. 3A) and lower distant metastasis-free survival (DMFS) (1746 samples, $p=$ 0.064, HR $=$ 1.2) (Fig. 3B) than patients with low levels of Smac/DIABLO. These data suggested that high levels of Smac/DIABLO expression are associated with a poor prognosis in breast cancer patients. To analyze whether the effect of Smac/DIABLO on survival was dependent on ER status, we considered only patients with ER-positive tumors for the survival analysis and found that, in this group of patients, high levels of Smac/DIABLO were associated to a worse OS (548 samples, $p=$ 0.021, HR $=$ 1.51) (Fig. 3C) and DMFS (664 samples, $p=$ 0.000073, HR $=$ 2.02) (Fig. 3D), in comparison with those patients with low levels of Smac/DIABLO. Next, we analyzed only ER-negative samples and conversely, we found that patients with ER-negative tumors and high expression of Smac/DIABLO showed a better prognosis than those with low expression of Smac/DIABLO, although this association was not statistically significant (OS, 251 samples, $p=$ 0.14, HR $=$ 0.7; DMFS, 218 samples, $p=$ 0.05, HR $=$ 0.62) (Fig. 3E and F, respectively). In the same database, with Smac/DIABLO protein expression assessed by RPPA, we found a similar trend on patient survival, although with no statistical significance. We found that patients with ER-positive tumors and high levels of Smac/DIABLO protein showed a trend for lower overall survival (OS) (627 samples, $p=$ 0.12, HR $=$ 1.52), while patients with ER-negative tumors and high levels of Smac/DIABLO protein showed a trend for better prognosis (196 samples, $p=$ 0.23, HR $=$ 0.61) (data not shown).

In conclusion, these data suggested that in breast cancer patients with ER-positive disease, there is an increase in the expression of both Smac/DIABLO mRNA and protein. In addition, high Smac/DIABLO expression is associated with poor prognosis, which depended on ER expression.

3.2 Smac/DIABLO levels are higher in ER-positive breast cancer cell lines

In order to gain more insight into the association between Smac/DIABLO and ER in breast cancer, we analyzed the expression of Smac/DIABLO by immunoblots in a panel of breast cancer cell lines with different ER status. We found higher levels of Smac/DIABLO in ER-positive breast cancer cell lines in comparison with ER-negative cells, as revealed by densitometric analyses (Fig. 4A–C). These results suggested for the first time a direct association between Smac/DIABLO and ER in breast cancer.

3.3 Estrogen receptor does not regulate Smac/DIABLO expression

Since ER is a known transcriptional factor, we sought to analyze whether Smac/DIABLO could be one of its targets. We exposed the ER-positive breast cancer cell lines MCF-7 and T47D to E2 (10 nM) for 24 h and analyzed Smac/DIABLO mRNA expression by qPCR. As a control, we also evaluated the expression of the pS2 gene, a known ER target gene. The expression of Smac/DIABLO was not regulated by the hormone exposure, while pS2 mRNA was upregulated in the presence of E2 in both cell lines, as shown in Fig. 5A and B. We analyzed whether the promoter of Smac/DIABLO could have estrogen-response elements (EREs). To this purpose, we used the TFBIND tool [27] (http://tfbind.hgc.jp/) to analyze the 1.5 kb region upstream of the transcription initiation site of Smac/DIABLO. This analysis revealed 2 putative EREs (Fig. 5C). Then to evaluate the functionality of these EREs, we cloned the 1.5 kb region of Smac/DIABLO gene in a reporter vector. We performed assays in MCF-7 cells to evaluate the gene reporter response to the E2 exposure. As expected by the previous results, there were no significant changes in the promoter activity under E2 exposure (Fig. 5D). As a control to determine the responsiveness to E2, we exposed non-transfected MCF-7 cells to the same treatment and evaluate the regulation of pS2 expression. pS2 expression was upregulated by E2 treatment under these conditions ( $p=$ 0.023) (Fig. 5E). These results demonstrated that ER neither regulate the expression of Smac/DIABLO mRNA nor acts as a transcriptional factor on its promoter.

Since it has been reported that overexpression of ER in breast cancer patients correlates with poorer prognosis in breast cancer patients [28, 29], we analyzed whether ER could regulate the expression of Smac/DIABLO in a model of LTED MCF-7 cells, where both an upregulation of ER and a hypersensitivity of its receptor have been observed [30]. To this purpose we cultured MCF-7 cells in estrogen-deprived conditions by five to seven months and as shown in Fig. 6A, we observed a two-fold increase in ER protein expression. When LTED MCF-7 cells were stimulated with E2 for 24 h we did not observe changes in Smac/DIABLO mRNA expression, whereas the known ER target pS2 was effectively upregulated (Fig. 6B). Next, we used the opposite strategy; we inhibited the ER expression in LTED MCF-7 cells with Fulvestrant, a known ER antagonist that induces downregulation of ER. Fulvestrant treatment efficiently inhibited ER protein expression, while Smac/DIABLO expression was not modulated (Fig. 6C and D). Thus, we conclude that Smac/DIABLO is not regulated by ER, neither in normal nor in estrogen-deprived conditions. Of note, that this is the first report where the regulation of Smac/DIABLO expression by ER in these conditions is studied.

3.4 Smac/DIABLO does not participate in the regulation of ER expression

Since it has been reported that Smac/DIABLO is able to modulate the expression of a number of proteins [31], we evaluated the participation of this protein on ER expression. For this, we transiently overexpressed Smac/DIABLO in MCF-7 cells and analyzed the ER protein by immunoblot. As shown in Fig. 7A and B, we successfully overexpressed Smac/DIABLO protein in these cells. Nevertheless, no change in ER protein was observed. Additionally, we analyzed ER mRNA levels in these cells by qPCR. As shown in Fig. 7C, mRNA levels of Smac/DIABLO were higher in overexpressing cells, while ER mRNA levels remained unchanged. We thus conclude that Smac/DIABLO does not participate in ER expression regulation in MCF-7 cells. Consequently, Smac/DIABLO role in breast cancer seems not to be directly mediated by ER regulation. These results suggest that another molecule(s) may modulate the function of Smac/DIABLO in breast cancer.

4. Discussion

Breast cancer remains the most common cancer in the female population worldwide. Clinical and molecular heterogeneity presents a challenge to estimate prognosis as well as the patients’ response to treatment. For these reasons there is a big research effort focused on finding new biomarkers to improve patient management. A widely used biomarker to estimate response to hormone therapy is ER expression, which is expressed in 50–80% of the breast tumors [32]. However, de novo or acquired resistance to hormone therapy remains a major clinical complication [33].

Smac/DIABLO is a proapoptotic protein that exerts its function through IAP inhibition. Altered expression of this protein has been observed in several tumors and, according to its proapoptotic function, reduced levels of Smac/DIABLO have been associated to poor prognosis in bladder, renal, and lung cancers [12, 13, 14]. However, in cervical cancer and leukemias, Smac/DIABLO expression is elevated in comparison with healthy tissue, and in the latter case, this increased expression was associated with poor prognosis [15, 34]. In breast cancer, several groups have analyzed Smac/DIABLO expression, with conflicting results. Pluta et al. [18] reported lower Smac/DIABLO protein levels in breast cancer patients and an inverse correlation with tumor stage. Mansour et al. [20]also found a diminished expression of Smac/DIABLO mRNA in tumor samples and an inverse correlation with survivin and ER [20]. In contrast, Zhang et al. [19] only observed that Smac/DIABLO protein expression was more prevalent in the HER2 positive group. These contradictory results could be attributed to the variability between the different populations analyzed, a reduced number of samples analyzed, the type of molecule (mRNA or protein) studied, and/or the diversity of employed techniques.

In the present study, we assessed the expression of Smac/DIABLO mRNA and protein in two independent groups of Mexican breast cancer patients. We analyzed the Smac/DIABLO mRNA expression by qPCR, while protein levels were assayed with immunohistochemistry. We found a higher expression of Smac/DIABLO mRNA in patients older than 50 years than in younger patients. This contrast with previous works showing a higher expression of Smac/DIABLO in patients younger than 50 years old [18, 35], and a lack of association with age [19, 20, 36]. We also found an inverse correlation between Smac/DIABLO mRNA expression and tumor grade in our samples. This result was in agreement with the recently reported study by Pluta et al., which showed an inverse correlation between Smac/DIABLO and grade [35]; although in previous works the authors did not found this association [18, 19, 20, 36]. It is important to mention that reduced Smac/DIABLO expression has been observed in more advanced tumors of the lung [14], in renal cell carcinoma [13], and germ cell tumors [37]. Even when Smac/DIABLO expression was observed in all samples, we found an increase in its mRNA in ER-positive tumors ( $p=$ 0.00468). This result contradicts other works, where an inverse association [20] or no association [18, 19] with the nuclear receptor were reported. These discordant results could be explained not only by the different techniques employed to analyze Smac/DIABLO levels, including semiquantitative PCR, flow cytometry and immunohistochemistry, but also for the small number of samples analyzed in previous reports.

Due to the antagonistic and closely related functions of Smac/DIABLO and survivin, an IAP family member [38, 39], the expression of both proteins in breast cancer has also been previously analyzed. Mansour et al., analyzed the expression of Smac/DIABLO and survivin by semiquantitative PCR and found a significant inverse correlation between these two genes [20]. Accordingly, in a recent study from Zhao and coworkers, the expression of both proteins was analyzed by immunohistochemistry, and a negative association between both proteins was reported ( $r=-$ 0.217, $p=$ 0.032) [36]. We also analyzed the expression of survivin by qPCR and, opposed to previous reports we found a negligible positive correlation between survivin and Smac/DIABLO ( $R=$ 0.23, $p>$ 0.05). These differences could be due to the different methods used to detect the expression of these molecules; quantitative PCR is more accurate than semiquantitative PCR, and in addition protein levels, measured by immunohistochemistry may not reflect mRNA levels due to posttranscriptional or postraductional mechanisms of regulation. Additionally, this may be due to the small number of samples analyzed. Nevertheless, when we considered the expression of both genes, we observed that a lower Smac/survivin ratio (low levels of Smac/DIABLO and high levels of survivin) showed a significant association with higher tumor size, and more advanced grade and stage ( $p=$ 0.0045, $p=$ 0.0017, $p=$ 0.0130, respectively). This result was concordant with the roles of both proteins in apoptosis, since lower levels of Smac/survivin ratio means higher levels of survivin than Smac/DIABLO, which could result in an impaired apoptotic process and breast cancer development [20]. A similar balance of these two genes has been associated to poor prognosis not only in breast cancer [20, 36], but also in serous ovarian carcinoma, leukemia and non-small-cell lung cancer [22, 23, 25]. We also analyzed the correlation between survivin expression and the clinicopathological characteristics of our patients. We only found higher levels of survivin mRNA in tumors with a size $>$ 2 cm, and no association with any other clinicopathological characteristics. Previously, Xu et al., showed that higher mRNA levels of survivin correlated with tumor progression and poor prognosis in a cohort of 245 breast cancer patients [40]. This discrepancy could be attributed to the small number of samples analyzed.

Next we analyzed Smac/DIABLO levels by immunohistochemistry in a different panel of tumor samples. In agreement with previous reports in breast cancer and other tumors [19, 34, 41], we observed that Smac/DIABLO staining showed cytosolic distribution. Practically all tumor cells (80–100%) presented this protein signal pattern. In contrast to previous reports where an inverse correlation between Smac/DIABLO and ER [20] or, no correlation was observed [18, 19, 35, 36], we found an increase in Smac/DIABLO expression in ER-positive tumors (Table 5; Fig. 1B), as we had previously observed at the mRNA level. These discordant results could be explained, as mentioned before, by the different techniques employed to assess Smac/DIABLO levels and the reduced number of samples analyzed. Interestingly, this is the first report where Smac/DIABLO mRNA and protein levels were positively associated with ER in breast cancer samples. These results were supported by data derived from public databases, where a high number of samples were available, and where a positive correlation between Smac/DIABLO and ER expression was also observed.

In line with the association between Smac/DIABLO and ER, we found that Smac/DIABLO may have an ER-dependent role in the prognosis of breast cancer patients. Our search in an online database revealed that high expression of Smac/DIABLO in ER-positive patients is associated with poor prognosis, whereas in ER-negative patients correlates with a good prognosis. It has been observed that high levels of Smac/DIABLO and lack of ER are independent predictors of pathological complete response (pCR) in patients with locally advanced breast cancer treated with neoadjuvant chemotherapy (anthracyclines) [36]. Additionally, high levels of Smac/DIABLO were associated with a complete remission (pCR) and a better disease-free survival, also in locally advanced breast cancer [35]. As expected, due to its proapoptotic function, high levels of Smac/DIABLO could be associated with a good prognosis since chemotherapy kill cancer cells by inducing apoptosis. However, in accordance with our findings, it has been proposed that apoptosis is important to progression and metastasis of cancer [42]. Even in breast cancer, a high apoptotic index (AI) has been associated with more aggressive tumors [43, 44, 45] and poor prognosis [43, 45]. In support of this role of apoptosis in breast cancer progression, it has been reported that high expression of BCL-2, an antiapoptotic protein, was associated to a good prognosis [46], while high levels of BIK (Bcl-2 interacting killer), a proapoptotic member of the BCL-2 family, were associated to a poor prognosis in this malignancy [47]. Additionally, high expression of caspase-3 protein has been associated to poor prognosis in breast cancer [48]. In addition, in melanoma, low expression of proapoptotic proteins Bax, Bak and Smac/DIABLO was associated with a better prognosis [49]. These counterintuitive results can be explained by several reports that demonstrated that apoptosis is able to induce proliferation and expansion of more aggressive clones to induce tumor growth and invasion [50, 51]. Accordingly, we found in our analysis of TCGA data that Smac/DIABLO protein levels were higher in Luminal B subtype samples in comparison with Basal subtype ones (Fig. 2D). Although Luminal B and Luminal A subtypes of breast cancer are ER-positive, the former shows a higher proliferative index and a higher risk of relapse than Luminal A subtype [52]. In line with these observations, our group reported that overexpression of a new alternative splice variant of Smac/DIABLO increased mammospheres formation derived from the MCF-7 breast cancer cell line. Whole-genome expression analysis from these mammospheres revealed the activation of cell survival and proliferation pathways. ER signaling network was one of them since transcriptional activation of estrogen-responsive genes (PGR, GREB1, PDZK1, and RAB31) was induced by the new Smac/DIABLO variant [53]. Of relevance, this new isoform of Smac lacks of a mitochondrial targeting sequence and of the domain for IAP binding [53], possibly affecting its proapoptotic function. Finally, as mentioned above, BIK can induce a more aggressive phenotype of breast cancer, even though induces a limited cell death [47]. In this regard, even when the pro-apoptotic function of Smac/DIABLO is thought to be IAP-dependent [9, 10, 54] additional mechanisms have been proposed [55]. Moreover, an apoptosis-independent role of Smac/DIABLO in tumor growth inhibition has been described [31] and non-apoptotic functions of Smac/DIABLO related to cancer initiation and progression involving synthesis of lipids, transport of ions, production of exosomes and inflammation have been also proposed [56]. Therefore, Smac/DIABLO functions in cancer have not been fully elucidated.

To validate our initial findings, we assessed the expression of Smac/DIABLO in several breast cancer cell lines with different ER status and found that higher levels of Smac/DIABLO were present in ER-positive breast cancer cell lines. This result agrees with our results derived from tumor samples. Unfortunately, we did not find evidence for an ER-dependent Smac/DIABLO regulation using several approaches. Although it is known that ER regulates genes related to apoptosis, such as Bcl-2, Bcl-xL, survivin, Caspase-9, Puma, Noxa and TRAILR3 [57, 58, 59] to promote cell proliferation, there are no reports about Smac/DIABLO regulation by this transcriptional factor. In agreement with our results, previous data from microarrays performed in breast cancer cell lines aimed to identify target genes for ER did not reveal regulation of Smac/DIABLO [60, 61]. However, the identification of ER target genes is very complex due to the participation of several mechanisms of regulation in its signaling pathway. For this reason, several strategies to identify its target genes have been employed, and there is no consensus between all results [62, 63]. Additionally, a common observation in breast cancer is the overexpression of ER, and higher levels of the receptor have been associated with a poor prognosis in comparison with those patients with low levels of ER. Interestingly, it has been reported that elevated levels of ER can induce aberrant activation of the receptor, even in the absence of the ligand [64]. Clinically, the growth of a breast tumor in an E2-independent way is a mechanism of resistance to hormonal therapy [30]. To study this in vitro, a model for E2 independence has been established by long-term estrogen-deprivation culture of MCF-7 cells, where an increase of twofold in ER levels has been observed [65]. We took advantage of this model to analyze if Smac/DIABLO expression could be regulated by ER. Following our previous experiments, we did not find evidence of ER-mediated regulation of Smac/DIABLO. We conclude that Smac/DIABLO is not a target gene of ER, even in estrogen-deprived conditions, so we do not support this mechanism as an explanation for the poor prognosis of breast cancer patients with ER-positive disease and high levels of Smac/DIABLO. The mechanism of Smac/DIABLO and ER co-expression, and its association with poor prognosis seems be different from that of the proapoptotic protein BIK, which shows a poor prognostic value in ER-positive breast tumors and its expression is regulated by ER [47]. Finally, we explored the possibility that Smac/DIABLO could regulate ER expression. We did not find neither ER mRNA nor protein modulation in response to Smac/DIABLO overexpression. Taking together these results, we conclude that the co-expression of Smac/DIABLO and ER is not due to a direct regulation between them, at least in our experimental conditions. This opens the possibility that another protein or molecule could regulate the expression of both proteins.

It is important to mention that our study has some limitations. We analyzed Smac/DIABLO mRNA and protein expression in two small groups of breast cancer patients; the first one with 57 samples and the second one with 82, so this could be the reason to the difference we observed with regard to previous works. In addition, although we found higher levels of Smac/DIABLO mRNA and protein in ER-positive breast cancer samples, these results were derived from two independent sets of samples. It would be very interesting to perform the analyses in the same samples to find a direct correlation between mRNA and protein levels. In addition, in our study we did not analyze the expression of Smac/DIABLO in adjacent normal tissue or healthy samples, which would add important information about the regulation of Smac/DIABLO in our samples. Finally, an important limitation of our work, was the lack of OS and DMFS information from our patients. This information is essential in order to evaluate the effects of the coexpression of Smac/DIABLO and ER on the survival of the patients involved in the present study. For all the reasons mentioned above, we analyzed public datasets and perform additional assays to support our findings but recognize that further investigation is needed.

Altogether, our data suggest that Smac/DIABLO and ER are co-expressed in breast tumor samples. However, we could not find any direct regulatory mechanism between these two proteins that could explain their association. Interestingly, a prognostic ER-dependent role for Smac/DIABLO was supported by online databases, and further studies are required to delve into this.

Footnotes

Acknowledgments

We thank PhD Oscar Vladimir Orduña Trujillo for his help with statistical analysis. This work was supported by Consejo Nacional de Ciencia y Tecnología (CONACyT) grants 87688 and 79838, and the National Institute of Genomic Medicine grant 013/2008.

Conflict of interest

The authors declare that they have no conflict of interest.

Authors’ contributions

ME, RG, KV, PP, AH, JT, VM INTERPRETATION OR ANALYSIS OF DATA, PREPARATION OF THE MANUSCRIPT.

FL PREPARATION OF THE MANUSCRIPT.

JM REVISION FOR IMPORTANT INTELECTUAL CONTENT.

GC CONCEPTION, INTERPRETATIONS OR ANALYSIS OF DATA, PREPARATION OF THE MANUSC- RIPT.

References

Bray

Ferlay

Soerjomataram

Siegel

R.L.

Torre

L.A.

and Jemal

, Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA Cancer J Clin 68 (2018), 394–424.

Reynoso-Noveron

Villarreal-Garza

Soto-Perez-de-Celis

Arce-Salinas

Matus-Santos

Ramirez-Ugalde

M.T.

Alvarado-Miranda

Cabrera-Galeana

Meneses-Garcia

Lara-Medina

Bargallo-Rocha

and Mohar

, Clinical and epidemiological profile of breast cancer in Mexico: results of the seguro popular, J Glob Oncol 3 (2017), 757–764.

Chavarri-Guerra

Villarreal-Garza

Liedke

P.E.

Knaul

Mohar

Finkelstein

D.M.

and Goss

P.E.

, Breast cancer in Mexico: a growing challenge to health and the health system, Lancet Oncol 13 (2012), e335–343.

Howlader

N.A.

Krapcho

Miller

Brest

Ruhl

Tatalovich

Mariotto

Lewis

D.R.

Chen

H.S.

Feuer

E.J.

Cronin

K.A.

, eds, SEER Cancer Statistics Review, 1975–2016, National Cancer Institute. Bethesda, MD, https://seer.cancer.gov/csr/1975_2016/, Accessed February 19, 2020. (2019).

Weigelt

Peterse

J.L.

and van ’t Veer

L.J.

, Breast cancer metastasis: markers and models, Nat Rev Cancer 5 (2005), 591–602.

Cadoo

K.A.

Fornier

M.N.

and Morris

P.G.

, Biological subtypes of breast cancer: current concepts and implications for recurrence patterns, Q J Nucl Med Mol Imaging 57 (2013), 312–321.

Dos Anjos Pultz

da Luz

F.A.

de Faria

P.R.

Oliveira

A.P.

de Araujo

R.A.

and Silva

M.J.

, Far beyond the usual biomarkers in breast cancer: a review, J Cancer 5 (2014), 559–571.

Hanahan

and Weinberg

R.A.

, Hallmarks of cancer: the next generation, Cell 144 (2011), 646–674.

Fang

and Wang

, Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition, Cell 102 (2000), 33–42.

10.

Verhagen

A.M.

Ekert

P.G.

Pakusch

Silke

Connolly

L.M.

Reid

G.E.

Moritz

R.L.

Simpson

R.J.

and Vaux

D.L.

, Identification of DIABLO, a mammalian protein that promotes apoptosis by binding to and antagonizing IAP proteins, Cell 102 (2000), 43–53.

11.

Ceballos-Cancino

Espinosa

Maldonado

and Melendez-Zajgla

, Regulation of mitochondrial Smac/ DIABLO-selective release by survivin, Oncogene 26 (2007), 7569–7575.

12.

Mizutani

Katsuoka

and Bonavida

, Prognostic significance of second mitochondria-derived activator of caspase (Smac/DIABLO) expression in bladder cancer and target for therapy, Int J Oncol 37 (2010), 503–508.

13.

Mizutani

Nakanishi

Yamamoto

Y.N.

Matsubara

Mikami

Okihara

Kawauchi

Bonavida

and Miki

, Downregulation of Smac/DIABLO expression in renal cell carcinoma and its prognostic significance, J Clin Oncol 23 (2005), 448–454.

14.

Sekimura

Konishi

Mizuno

Kobayashi

Sasaki

Yano

Fukai

and Fujii

, Expression of Smac/DIABLO is a novel prognostic marker in lung cancer, Oncol Rep 11 (2004), 797–802.

15.

Espinosa

Cantu

Lopez

C.M.

De la Garza

J.G.

Maldonado

V.A.

and Melendez-Zajgla

, SMAC is expressed de novo in a subset of cervical cancer tumors, BMC Cancer 4 (2004), 84.

16.

Shibata

Mahotka

Wethkamp

Heikaus

Gabbert

H.E.

and Ramp

, Disturbed expression of the apoptosis regulators XIAP, XAF1, and Smac/DIABLO in gastric adenocarcinomas, Diagn Mol Pathol 16 (2007), 1–8.

17.

Wang

and Zhou

J.H.

, Expressions of c-IAP2 and Smac gene in leukemia and their clinical significance, Zhongguo Shi Yan Xue Ye Xue Za Zhi 14 (2006), 217–220.

18.

Pluta

Cebula-Obrzut

Ehemann

Pluta

Wierzbowska

Piekarski

Bilski

Nejc

Kordek

Robak

Smolewski

and Jeziorski

, Correlation of Smac/DIABLO protein expression with the clinico-pathological features of breast cancer patients, Neoplasma 58 (2011), 430–435.

19.

Zhang

Zhu

Tang

Zhou

Peng

Zhou

and Fu

, X-linked inhibitor of apoptosis positive nuclear labeling: a new independent prognostic biomarker of breast invasive ductal carcinoma, Diagn Pathol 6 (2011), 49.

20.

Mansour

Nabil

Ali-Labib

Said

and Annos

, Reciprocal expression of survivin and SMAC/DIABLO in primary breast cancer, Med Oncol 29 (2012), 2535–2542.

21.

Martinez-Velazquez

Melendez-Zajgla

and Maldonado

, Apoptosis induced by cAMP requires Smac/DIABLO transcriptional upregulation, Cell Signal 19 (2007), 1212–1220.

22.

Dobrzycka

Mackowiak-Matejczyk

Terlikowska

K.M.

Kulesza-Bronczyk

Kinalski

and Terlikowski

S.J.

, Prognostic significance of pretreatment VEGF, survivin, and Smac/DIABLO serum levels in patients with serous ovarian carcinoma, Tumour Biol (2015).

23.

Grzybowska-Izydorczyk

Cebula

Robak

and Smolewski

, Expression and prognostic significance of the inhibitor of apoptosis protein (IAP) family and its antagonists in chronic lymphocytic leukaemia, Eur J Cancer 46 (2010), 800–810.

24.

Dai

C.H.

Shi

S.B.

L.C.

L.P.

and Chen

, Survivin and Smac gene expressions but not livin are predictors of prognosis in non-small cell lung cancer patients treated with adjuvant chemotherapy following surgery, Jpn J Clin Oncol 40 (2010), 327–335.

25.

Chen

L.P.

Dai

C.H.

and Li

X.Q.

, Prognostic value of survivin, X-linked inhibitor of apoptosis protein and second mitochondria-derived activator of caspases expression in advanced non-small-cell lung cancer patients, Respirology 15 (2010), 501–509.

26.

Gyorffy

Lanczky

Eklund

A.C.

Denkert

Budczies

and Szallasi

, An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients, Breast Cancer Res Treat 123 (2010), 725–731.

27.

Tsunoda

and Takagi

, Estimating transcription factor bindability on DNA, Bioinformatics 15 (1999), 622–630.

28.

Black

Prescott

Bers

Hawkins

Stewart

and Forrest

, Tumour cellularity, oestrogen receptors and prognosis in breast cancer, Clin Oncol 9 (1983), 311–318.

29.

Thorpe

S.M.

Christensen

I.J.

Rasmussen

B.B.

and Rose

, Short recurrence-free survival associated with high oestrogen receptor levels in the natural history of postmenopausal, primary breast cancer, Eur J Cancer 29A (1993), 971–977.

30.

Chan

C.M.

Martin

L.A.

Johnston

S.R.

Ali

and Dowsett

, Molecular changes associated with the acquisition of oestrogen hypersensitivity in MCF-7 breast cancer cells on long-term oestrogen deprivation, J Steroid Biochem Mol Biol 81 (2002), 333–341.

31.

Vogler

Giagkousiklidis

Genze

Gschwend

J.E.

Debatin

K.M.

and Fulda

, Inhibition of clonogenic tumor growth: a novel function of Smac contributing to its antitumor activity, Oncogene 24 (2005), 7190–7202.

32.

Huang

Warner

and Gustafsson

J.A.

, Estrogen receptors in breast carcinogenesis and endocrine therapy, Mol Cell Endocrinol (2014).

33.

Ziauddin

M.F.

Hua

and Tang

S.C.

, Emerging strategies to overcome resistance to endocrine therapy for breast cancer, Cancer Metastasis Rev 33 (2014), 791–807.

34.

Arellano-Llamas

Garcia

F.J.

Perez

Cantu

Espinosa

De la Garza

J.G.

Maldonado

and Melendez-Zajgla

, High Smac/DIABLO expression is associated with early local recurrence of cervical cancer, BMC Cancer 6 (2006), 256.

35.

Pluta

Jesionek-Kupnicka

Kubicka-Wolkowska

Pluta

Brzozowski

Potemski

Piekarski

Kordek

and Jeziorski

, SMAC protein expression as a potent favorable prognostic factor in locally advanced breast cancer, Pol J Pathol 69 (2018), 33–41.

36.

Zhao

Y.C.

Wang

X.J.

Wang

X.M.

Zhu

Y.Y.

and Luo

C.Y.

, Clinical significance of Smac and survivin expression in breast cancer patients treated with anthracyclinebased neoadjuvant chemotherapy, Mol Med Rep 9 (2014), 614–620.

37.

Kempkensteffen

Jager

Bub

Weikert

Hinz

Christoph

Krause

Schostak

Miller

and Schrader

, The equilibrium of XIAP and Smac/DIABLO expression is gradually deranged during the development and progression of testicular germ cell tumours, Int J Androl 30 (2007), 476–483.

38.

Kim

J.Y.

Chung

J.Y.

Lee

S.G.

Kim

Y.J.

Park

J.E.

Yoo

K.S.

Yoo

Y.H.

Park

Y.C.

Kim

B.G.

and Kim

J.M.

, Nuclear interaction of Smac/DIABLO with Survivin at G2/M arrest prompts docetaxel-induced apoptosis in DU145 prostate cancer cells, Biochem Biophys Res Commun 350 (2006), 949–954.

39.

Song

Yao

and Wu

, Direct interaction between survivin and Smac/DIABLO is essential for the anti-apoptotic activity of survivin during taxol-induced apoptosis, J Biol Chem 278 (2003), 23130–23140.

40.

Yamamoto-Ibusuki

Yamamoto

Fujiwara

Murakami

Okumura

Yamaguchi

Fujiki

and Iwase

, High survivin mRNA expression is a predictor of poor prognosis in breast cancer: a comparative study at the mRNA and protein level, Breast Cancer 21 (2014), 482–490.

41.

Shintani

Sangawa

Yamao

and Kamoshida

, Smac/DIABLO expression in human gastrointestinal carcinoma: Association with clinicopathological parameters and survivin expression, Oncol Lett 8 (2014), 2581–2586.

42.

Wang

R.A.

Q.L.

Z.S.

Zheng

P.J.

Zhang

H.Z.

Huang

X.F.

Chi

S.M.

Yang

A.G.

and Cui

, Apoptosis drives cancer cells proliferate and metastasize, J Cell Mol Med 17 (2013), 205–211.

43.

Zhang

G.J.

Kimijima

Abe

Watanabe

Kanno

Hara

and Tsuchiya

, Apoptotic index correlates to bcl-2 and p53 protein expression, histological grade and prognosis in invasive breast cancers, Anticancer Res 18 (1998), 1989–1998.

44.

Zheng

W.Q.

and Zhan

R.Z.

, Quantitative comparison of apoptosis to cell proliferation and p53 protein in breast carcinomas, Anal Quant Cytol Histol 20 (1998), 1–6.

45.

Boder

Abdalla

Elfagieh

Buhmeida

and Collan

, Apoptotic activity in Libyan breast cancer, World J Surg Oncol 10 (2012), 102.

46.

Dawson

S.J.

Makretsov

Blows

F.M.

Driver

K.E.

Provenzano

Le Quesne

Baglietto

Severi

Giles

G.G.

McLean

C.A.

Callagy

Green

A.R.

Ellis

Gelmon

Turashvili

Leung

Aparicio

Huntsman

Caldas

and Pharoah

, BCL2 in breast cancer: a favourable prognostic marker across molecular subtypes and independent of adjuvant therapy received, Br J Cancer 103 (2010), 668–675.

47.

Pandya

Githaka

J.M.

Patel

Veldhoen

Hugh

Damaraju

McMullen

Mackey

and Goping

I.S.

, BIK drives an aggressive breast cancer phenotype through sublethal apoptosis and predicts poor prognosis of ER-positive breast cancer, Cell Death Dis 11 (2020), 448.

48.

Storr

S.J.

Zhang

Rakha

E.A.

Green

A.R.

Ellis

I.O.

and Martin

S.G.

, Caspase-3 and caspase-8 expression in breast cancer: caspase-3 is associated with survival, Apoptosis 22 (2017), 357–368.

49.

Gutta

Rahman

Aura

Dynoodt

Charles

E.M.

Hirschenhahn

Joseph

Wouters

de Chaumont

Rafferty

Warren

van den Oord

J.J.

Gallagher

W.M.

and Rehm

, Low expression of pro-apoptotic proteins Bax, Bak and Smac indicates prolonged progression-free survival in chemotherapy-treated metastatic melanoma, Cell Death Dis 11 (2020), 124.

50.

Labi

and Erlacher

, How cell death shapes cancer, Cell Death Dis 6 (2015), e1675.

51.

Perez-Garijo

and Steller

, Spreading the word: non-autonomous effects of apoptosis during development, regeneration and disease, Development 142 (2015), 3253–3262.

52.

Tran

and Bedard

P.L.

, Luminal-B breast cancer and novel therapeutic targets, Breast Cancer Res 13 (2011), 221.

53.

Martinez-Ruiz

G.U.

Victoria-Acosta

Vazquez-Santillan

K.I.

Jimenez-Hernandez

Munoz-Galindo

Ceballos-Cancino

Maldonado

and Melendez-Zajgla

, Ectopic expression of new alternative splice variant of Smac/ DIABLO increases mammospheres formation, Int J Clin Exp Pathol 7 (2014), 5515–5526.

54.

Chai

Suber

T.L.

J.W.

Wang

and Shi

, Structural basis of IAP recognition by Smac/DIABLO, Nature 408 (2000), 1008–1012.

55.

Roberts

D.L.

Merrison

MacFarlane

and Cohen

G.M.

, The inhibitor of apoptosis protein-binding domain of Smac is not essential for its proapoptotic activity, J Cell Biol 153 (2001), 221–228.

56.

Paul

Krelin

Arif

Jeger

and Shoshan-Barmatz

, A new role for the mitochondrial pro-apoptotic protein SMAC/diablo in phospholipid synthesis associated with tumorigenesis, Mol Ther 26 (2018), 680–694.

57.

Leung

L.K.

and Wang

T.T.

, Paradoxical regulation of Bcl-2 family proteins by 17beta-oestradiol in human breast cancer cells MCF-7, Br J Cancer 81 (1999), 387–392.

58.

Frasor

Danes

J.M.

Komm

Chang

K.C.

Lyttle

C.R.

and Katzenellenbogen

B.S.

, Profiling of estrogen up- and down-regulated gene expression in human breast cancer cells: insights into gene networks and pathways underlying estrogenic control of proliferation and cell phenotype, Endocrinology 144 (2003), 4562–4574.

59.

Tozlu

Girault

Vacher

Vendrell

Andrieu

Spyratos

Cohen

Lidereau

and Bieche

, Identification of novel genes that co-cluster with estrogen receptor alpha in breast tumor biopsy specimens, using a large-scale real-time reverse transcription-PCR approach, Endocr Relat Cancer 13 (2006), 1109–1120.

60.

Glidewell-Kenney

Weiss

Lee

E.J.

Pillai

Ishikawa

Ariazi

E.A.

and Jameson

J.L.

, ERE-independent ERalpha target genes differentially expressed in human breast tumors, Mol Cell Endocrinol 245 (2005), 53–59.

61.

Huan

Wang

Xing

Qin

Feng

Pan

and Zhu

, Insights into significant pathways and gene interaction networks underlying breast cancer cell line MCF-7 treated with 17beta-estradiol (E2), Gene 533 (2014), 346–355.

62.

Welboren

W.J.

Sweep

F.C.

Span

P.N.

and Stunnenberg

H.G.

, Genomic actions of estrogen receptor alpha: what are the targets and how are they regulated? Endocr Relat Cancer 16 (2009), 1073–1089.

63.

Manavathi

Dey

Gajulapalli

V.N.

Bhatia

R.S.

Bugide

and Kumar

, Derailed estrogen signaling and breast cancer: an authentic couple, Endocr Rev 34 (2013), 1–32.

64.

Fowler

A.M.

Solodin

Preisler-Mashek

M.T.

Zhang

Lee

A.V.

and Alarid

E.T.

, Increases in estrogen receptor-alpha concentration in breast cancer cells promote serine 118/104/106-independent AF-1 transactivation and growth in the absence of estrogen, FASEB J 18 (2004), 81–93.

65.

Jeng

M.H.

Shupnik

M.A.

Bender

T.P.

Westin

E.H.

Bandyopadhyay

Kumar

Masamura

and Santen

R.J.

, Estrogen receptor expression and function in long-term estrogen-deprived human breast cancer cells, Endocrinology 139 (1998), 4164–4174.

Coexpression of Smac/DIABLO and Estrogen Receptor in breast cancer

Abstract

BACKGROUND:

OBJECTIVE:

METHODS:

RESULTS:

CONCLUSIONS:

Keywords

1. Introduction

2. Materials and methods

2.1 Patients

2.2 Tissue microarray construction

2.3 Immunohistochemistry of breast cancer tissues

2.4 The Cancer Genome Atlas (TCGA) samples

2.5 Cell lines

2.6 Protein extraction

2.7 Western blot

2.8 Chemicals

2.9 Plasmids

2.10 RT and qPCR

2.11 E2 treatment

2.12 Gene reporter assays

2.13 Long-term estrogen-deprived (LTED) MCF-7 cells establishment and experiments

2.14 Cell transfection

2.15 Statistical analysis

3. Results

3.1 Smac/DIABLO expression is higher in ER-positive breast tumors and is associated with a worse prognosis in breast cancer patients

Table 1 Clinicopathological features of mRNA analysis breast cancer group ( N = 57)

3.3 Estrogen receptor does not regulate Smac/DIABLO expression

3.4 Smac/DIABLO does not participate in the regulation of ER expression

4. Discussion

Footnotes

Acknowledgments

Conflict of interest

Authors’ contributions

References

Table 1
Clinicopathological features of mRNA analysis breast cancer group ( $N=$ 57)